Institut Curie

Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice.
Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupé P, Bourhis J, Hall J, Fontaine JJ, Vozenin MC.
Sci Transl Med. 2014 Jul 16;6(245):245ra93.

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.
Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, Gentien D, Servant N, Gestraud P, Rio Frio T, Hupé P, Barillot E, Laes JF.
Bioinformatics. 2014 Dec 15;30(24):3443-50.

Biological network modelling and precision medicine in oncology
Calzone L, Kuperstein I, Cohen D, Grieco L, Bonnet E, Servant N, Hupé P, Zinovyev A, Barillot E.
Bull Cancer. 2014 Jun;101 Suppl 1:S18-21.

Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.
Servant N, Roméjon J, Gestraud P, La Rosa P, Lucotte G, Lair S, Bernard V, Zeitouni B, Coffin F, Jules-Clément G, Yvon F, Lermine A, Poullet P, Liva S, Pook S, Popova T, Barette C, Prud'homme F, Dick JG, Kamal M, Le Tourneau C, Barillot E, Hupé P.
Front Genet. 2014 May 30;5:152.

Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.
Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, Bedossa P, De Koning L, Danelsky C, Dubois T, Hupé P, Louvard D, Lallemand D.
Neuro Oncol. 2014 Sep;16(9):1196-209.

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E. Clin Cancer Res. 2014 Aug 15;20(16):4314-25.

Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.
Verlingue L., Alt M., Kamal M., Sablin MP., Zoubir M., Bousetta N., Pierga JY, Servant N., Paoletti X., Le Tourneau C. et al. Personalized Medicine 2014;11(5), 545-558

Epigenomic alterations in breast carcinoma from primary tumor to locoregional recurrences.
Moarii M., Pinheiro A., Sigal-Zafrani B., Fourquet A., Caly M., Servant N, Stoven V. Vert JP., Reyal F. PLoS One 2014;9:e103986

Combinatorial flexibility of cytokine function during human T helper cell differentiation.
Touzot M., Grandclaudon M., Cappuccio A., Satoh T., Martinez-Cingolani C., Servant N., Manel N., Soumelis V.
Nat Commun 2014;5:3987.

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A., Servois V., Romejon J., Mariani O., Bernard V., Hupé P., Pierron G., Mulot F., Callens C., Wong J., Mauborgne C., Rouleau E., Reyes C., Henry E., Leroy Q., Gestraud P., La Rosa P., Escalup L., Mitry E. Trédan O., Delord JP., Campone M., Goncalves A., Isambert N., Gavoille C., Kamal M.
Br J Cancer 2014;111:17-24.

Developmental dynamics and disease potential of random monoallelic gene expression.
Gendrel AV, Attia M, Chen CJ, Diabangouaya P, Servant N, Barillot E, Heard E.
Dev Cell 2014;28:366-80.

Mutational analysis of primary central nervous system lymphoma.
Bruno A, Labrèche K, Boisselier B, Marie Y, Houillier C, Aidaoui B, Daveau R, Hoang Xuan K. Oncotarget. 2014 Jul 15;5(13):5065-75.

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Cazes A, Lopez-Delisle L, Tsarovina K, Pierre-Eugène C, De Preter K, Peuchmaur M, Nicolas A, Provost C, Louis-Brennetot C, Daveau R, Kumps C, Cascone I, Schleiermacher G, Prignon A, Speleman F, Rohrer H, Delattre O, Janoueix-Lerosey I.
Oncotarget. 2014 May 15;5(9):2688-702.

Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes
Anne Biton, Isabelle Bernard-Pierrot, Yinjun Lou, Clémentine Krucker, Elodie Chapeaublanc, Carlota Rubio-Pérez, Nuria López-Bigas, Aurélie Kamoun, Yann Neuzilletn, Pierre Gestraud, Luca Grieco, Sandra Rebouissou, Aurélien de Reyniès, Simone Benhamou, Thierry Lebret, Jennifer Southgate, Emmanuel Barillot, Yves Allory, Andrei Zinovyev, François Radvanyi
Cell Reports, Volume 9, Issue 4, p1235–1245, 20 November 2014

Cdc42 controls the dilation of the exocytotic fusion pore by regulating membrane tension.
Bretou M, Jouannot O, Fanget I, Pierobon P, Larochette N, Gestraud P, Guillon M, Emiliani V, Gasman S, Desnos C, Lennon-Duménil AM, Darchen F.
Mol Biol Cell. 2014 Oct 15;25(20):3195-209.

Human blood BDCA-1 dendritic cells differentiate into Langerhans-like cells with thymic stromal lymphopoietin and TGF-B.
Martínez-Cingolani C, Grandclaudon M, Jeanmougin M, Jouve M, Zollinger R, Soumelis V.
Blood Vol. 124(5).

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, Frio TR, Vaucher I, Raynal V, Bernard V, Lermine A, Clausen I, Giroud N, Schmucki R, Milder M, Horn C, Spleiss O, Lantz O, Stern MH, Pierga JY, Weisser M, Lebofsky R.
Int J Cancer. 2014 Oct 10.

Network Inference in Breast Cancer with Gaussian Graphical Models and extensions, in Probabilistic graphical models for genetics, Oxford University Press (book chapter)
Jeanmougin M, Charbonnier C, Guedj M, Chiquet J.